

BEXSERO Discussion Guide

Does my child really need to be vaccinated if MenB disease is uncommon?
Why is my child at risk?

What are meningitis and septicaemia? Can they have serious consequences?
Why should my child get this vaccine?

How is MenB different from MenACWY and how many meningococcal vaccines
are needed to help protect my child?

Why should my child be vaccinated against MenB now? Can we do it later?

What side effects may occur after receiving BEXSERO?

.....

Vaccination may not protect all vaccine recipients.²

Abbreviations: MenACWY: meningococcal groups A, C, W and Y; MenB: meningococcal group B

Reference: 1. Health NZ; Immunisation Handbook 2026 Version 2; 2026; 1-698. 2. GlaxoSmithKline New Zealand. BEXSERO Data Sheet. GSK NZ; 2024.

BEXSERO (Multicomponent meningococcal group B vaccine) is for immunisation against invasive disease caused by *N. meningitidis* group B from 2 months of age or per official recommendations. BEXSERO is a **prescription medicine** and is funded as part of the National Immunisation Schedule. See Pharmaceutical Schedule for full funding criteria. BEXSERO is also available for private purchase – normal doctor's fees apply. One 0.5 ml dose BEXSERO contains 50 mcg of each *N. meningitidis* group B component (Neisseria Heparin Binding Antigen fusion protein, Neisseria Adhesin A protein and Factor H Binding Protein fusion protein), as well as 25 mcg outer membrane vesicles from *N. meningitidis* group B strain NZ98/254. **BEXSERO has risks and benefits. Ask your doctor if BEXSERO is right for you. Use strictly as directed.** **Very common side effects** for infants, toddlers, and children (up to 10 years of age) include tenderness at the injection site, fever, and irritability. In adolescents (from 11 years of age) and adults, very common side effects are pain at the injection site, nausea, and headache. If you or your child have side effects, see your doctor. **For more information, including full product details, see BEXSERO Consumer Medicine Information at www.medsafe.govt.nz.** Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. GlaxoSmithKline NZ Ltd, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.** Date of Approval: 08.2026 Date of Expiry: 08.2028 TAPS NP25291-PM-NZ-BEX-PINF-260001